Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Adicionar filtros








Intervalo de ano
1.
EJB-Egyptian Journal of Biochemistry and Molecular Biology [The]. 2006; 24 (2): 130-152
em Inglês | IMEMR | ID: emr-182155

RESUMO

Hepatocellular carcinoma [HCC] is one of the most commonmalignancies in the world. Hepatocellular carcinoma is characterized by high vascularity, so tumor angiogenesis nowadays has been considered to be a strong prognostic factor in patients with HCC .The pre-therapeutic serum vascular endothelial growth factor[VEGF] and basic fibroblast growth factor [bFGF] levels in the HCC patients appear to reflect the disease's potential activity of vascular invasion and metastasis. The pre-therapeutic serum levels of the angiogenic factors VEGF and bFGF were detected in the sera of HCC patients to find new markers to be used for diagnosis of HCC, and were compared with the routinely used tumor markers used for diagnosis of HCC as AFP, CEA, and CA19.9. The relation between the serum levels of VEGF, and bFGF and the clinical characteristics of HCC was also elucidated. On comparing the studied tumor markers among the three studied groups, all the tumor markers were highest in the HCC group, followed the benign liver diseases, and lastly the normal control group [p-value= <0.001 each]. On comparing the studied tumor markers according to different prognostic factors, only AFP showed statistically significant result with the tumor size


Assuntos
Indutores da Angiogênese/sangue , Fator A de Crescimento do Endotélio Vascular/sangue , Biomarcadores Tumorais/sangue , Ascite , Prognóstico , Hospitais Universitários
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA